>However, Onyx only gets a 7% royalty from Japan.<
Even though Bayer exclusively funded the clinical development in Japan, a 7% royalty rate seems unduly low. I suppose this is the price for ONXX’s having inked favorable economic terms elsewhere in the world.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”